Fused aminopiperidines as dipeptidyi peptidase-IV inhibitors for the treatment or prevention of diabetes
View Patent ↗The present invention is directed to novel substituted fused aminopiperidines which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DPP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
1. A compound of structural formula I:
or a pharmaceutically acceptable salt thereof; wherein
m is 0 or 1;
each n is independently 0, 1, or 2;
Ar is phenyl unsubstituted or substituted with one to five R 2 substituents;
each R 2 is independently selected from the group consisting of fluorine, chlorine, methyl, and trifluoromethyl;
R 1 , R 7 and R 8 are each independently selected from the group consisting of
hydrogen,
hydroxy,
halogen,
C 1-10 alkoxy, wherein alkoxy is unsubstituted or substituted with one to five substituents independently selected from halogen or hydroxy,
C 1-10 alkyl, wherein alkyl is unsubstituted or substituted with one to five substituents independently selected from halogen or hydroxy,
C 1-10 alkenyl, unsubstituted or substituted with one to five substituents independently selected from halogen or hydroxy,
(CH 2 ) n —C 3-6 cycloalkyl, wherein cycloalkyl is unsubstituted or substituted with one to three substituents independently selected from halogen, hydroxy, cyano, CO 2 H, C 1-6 alkyloxycarbonyl, C 1-6 alkyl, and C 1-6 alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens,
wherein any individual methylene (CH 2 ) carbon atom in (CH 2 ) n is unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, C 1-4 alkyl, and C 1-4 alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens;
R 3 and R 4 are each independently selected from the group consisting of
hydrogen,
(CH 2 ) n -phenyl,
(CH 2 ) n —C 3-6 cycloalkyl, and
C 1-6 alkyl,
wherein alkyl is unsubstituted or substituted with one to five substituents independently selected from halogen and hydroxy and wherein phenyl and cycloalkyl are unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy, C 1-6 alkyl, and C 1-6 alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens;
or R 3 and R 4 together with the nitrogen atom to which they are attached form a heterocyclic ring selected from azetidine, pyrrolidine, piperidine, piperazine, and morpholine wherein said heterocyclic ring is unsubstituted or substituted with one to three substituents independently selected from halogen, hydroxy, C 1-6 alkyl, and C 1-6 alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens;
each R 5 is independently C 1-6 alkyl, wherein alkyl is unsubstituted or substituted with one to five substituents independently selected from halogen and hydroxy; and
R 6 is hydrogen or R 5 .
2. The compound of claim 1 wherein m is 0.
3. The compound of claim 1 wherein m is 1.
4. The compound of claim 1 wherein Ar is 2,4,5-trifluorophenyl or 2,5-difluorophenyl.
5. The compound of claim 1 wherein R 1 , R 7 and R 8 are each independently selected from the group consisting of
hydrogen,
halogen,
C 1-4 alkoxy, wherein alkoxy is unsubstituted or substituted with one to five fluorines,
C 1-4 alkyl, wherein alkyl is unsubstituted or substituted with one to five fluorines,
C 1-4 alkenyl, unsubstituted or substituted with one to five fluorines, and
C 3-6 cycloalkyl.
6. The compound of claim 5 wherein R 1 is hydrogen.
7. The compound of claim 1 of structural formula Ia or Ib having the indicated stereochemical configuration at the two stereogenic carbon atoms marked with an *:
8. The compound of claim 7 of structural formula Ia having the indicated absolute stereochemical configuration at the two stereogenic carbon atoms marked with an *:
9. The compound of claim 8 wherein m is 0; R 1 is hydrogen; Ar is 2,4,5-trifluorophenyl or difluorophenyl; and R 7 and R 8 are each independently selected from the group consisting of
hydrogen,
halogen,
C 1-4 alkoxy, wherein alkoxy is unsubstituted or substituted with one to five fluorines,
C 1-4 alkyl, wherein alkyl is unsubstituted or substituted with one to five fluorines,
C 1-4 alkenyl, unsubstituted or substituted with one to five fluorines, and
C 3-6 cycloalkyl.
10. The compound of claim 8 wherein m is 1; R 1 is hydrogen; Ar is 2,4,5-trifluorophenyl or difluorophenyl; and R 7 and R 8 are each independently selected from the group consisting of
hydrogen,
halogen,
C 1-4 alkoxy, wherein alkoxy is unsubstituted or substituted with one to five fluorines,
C 1-4 alkyl, wherein alkyl is unsubstituted or substituted with one to five fluorines,
C 1-4 alkenyl, wherein alkenyl is unsubstituted or substituted with one to five fluorines, and
C 3-6 cycloalkyl.
11. The compound of claim 8 which is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
12. The compound of claim 11 which is
or a pharmaceutically acceptable salt thereof.
13. The compound of claim 11 which is
or a pharmaceutically acceptable salt thereof.
14. The compound of claim 11 which is
or a pharmaceutically acceptable salt thereof.
15. A pharmaceutical composition which comprises a compound of claim 1 and a pharmaceutically acceptable carrier.
16. The pharmaceutical composition of claim 15 additionally comprising metformin.
17. A method of treating Type 2 diabetes comprising administering a therapeutically effective amount of a compound of claim 1 to a patient in need thereof.